Spotlight On... Shire, Baxalta in late-stage talks on $32B tie-up: Bloomberg; Hikma wins FDA approval for surgery recovery drug; NICE does about-face on Merck's Ezetrol; and more...

Shire ($SHPG) is finally nearing the Baxalta ($BXLT) buyout it's long coveted, according to Bloomberg's sources. The two drugmakers are discussing a price between $46.50 and $48 per share, the news service reports, which would value the Illinois pharma at about $32 billion. A tie-up, Shire CEO Flemming Ornskov has said, would create a global rare-disease leader that can bring in $20 billion in sales by 2020. More from FiercePharma

> Hikma Pharmaceuticals has won FDA approval to market a drug used to enable patients to recover from surgery. Release

> U.K. cost-effectiveness gatekeepers have changed their tune when it comes to using Merck's ($MRK) hypercholesterolemia med Ezetrol on the National Health Service, reverting back to original guidelines published in 2007. More

And Finally... Some say the three-year cancer battle of Mary Pazdur, wife of FDA oncology chief Richard Pazdur, increased his willingness to quickly approve risky new therapies. More (sub. req.)

Suggested Articles

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.

Mylan is taking coronavirus support to Sesame Street, backing Sesame Workshop's ongoing work to help children and parents cope with the pandemic.

Opdivo's wins in front-line gastric and esophageal cancers comes a year after Merck's Keytruda flopped in the same setting.